Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Equity Ratio (2021 - 2026)

Axsome Therapeutics' Equity Ratio history spans 6 years, with the latest figure at 0.08 for Q1 2026.

  • On a quarterly basis, Equity Ratio fell 14.21% to 0.08 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.08, a 14.21% decrease, with the full-year FY2025 number at 0.13, up 27.63% from a year prior.
  • Equity Ratio hit 0.08 in Q1 2026 for Axsome Therapeutics, down from 0.13 in the prior quarter.
  • Over the last five years, Equity Ratio for AXSM hit a ceiling of 0.46 in Q3 2022 and a floor of 0.08 in Q1 2026.
  • Historically, Equity Ratio has averaged 0.22 across 5 years, with a median of 0.17 in 2022.
  • Biggest five-year swings in Equity Ratio: surged 441.51% in 2023 and later crashed 69.11% in 2024.
  • Tracing AXSM's Equity Ratio over 5 years: stood at 0.33 in 2022, then fell by 1.77% to 0.32 in 2023, then crashed by 69.11% to 0.1 in 2024, then grew by 27.63% to 0.13 in 2025, then tumbled by 40.24% to 0.08 in 2026.
  • Business Quant data shows Equity Ratio for AXSM at 0.08 in Q1 2026, 0.13 in Q4 2025, and 0.11 in Q3 2025.